date: 2024-01-09T07:08:07Z
pdf:unmappedUnicodeCharsPerPage: 0
pdf:PDFVersion: 1.7
pdf:docinfo:title: The Designed Pore-Forming Antimicrobial Peptide C14R Combines Excellent Activity against the Major Opportunistic Human Pathogen Pseudomonas aeruginosa with Low Cytotoxicity
xmp:CreatorTool: LaTeX with hyperref
Keywords: antimicrobial peptides; clinical isolates; pore-formation; Pseudomonas aeruginosa
access_permission:modify_annotations: true
access_permission:can_print_degraded: true
subject: The diminishing portfolio of mankind?s available antibiotics urges science to develop novel potent drugs. Here, we present a peptide fitting the typical blueprint of amphipathic and membrane-active antimicrobial peptides, denominated C14R. This 2 kDa peptide consists of 16 amino acid residues, with seven being either hydrophobic, aromatic, or non-polar, and nine being polar or positively charged, strictly separated on opposite sides of the predicted -helix. The affinity of the peptide C14R to P. aeruginosa membranes and its intrinsic tendency to productively insert into membranes of such composition were analyzed by dynamic simulations. Its biological impact on the viability of two different P. aeruginosa reference strains was demonstrated by determining the minimal inhibitory concentrations (MICs), which were found to be in the range of 10?15 g/mL. C14R?s pore-forming capability was verified in a permeabilization assay based on the peptide-triggered uptake of fluorescent dyes into the bacterial cells. Finally, the peptide was used in radial diffusion assays, which are commonly used for susceptibility testing of antimicrobial peptides in clinical microbiology. In comparison to reference strains, six clinical P. aeruginosa isolates were clearly affected, thereby paving the way for further in-depth analyses of C14R as a promising new AMP drug in the future.
dc:creator: Vanessa Mildenberger, Daniel Alpízar-Pedraza, Ernesto M. Martell-Huguet, Markus Krämer, Grigory Bolotnikov, Anselmo J. Otero-Gonzalez, Tanja Weil, Armando Rodriguez-Alfonso, Nico Preising, Ludger Ständker, Verena Vogel, Barbara Spellerberg, Ann-Kathrin Kissmann and Frank Rosenau
dcterms:created: 2024-01-09T06:42:49Z
Last-Modified: 2024-01-09T07:08:07Z
dcterms:modified: 2024-01-09T07:08:07Z
dc:format: application/pdf; version=1.7
title: The Designed Pore-Forming Antimicrobial Peptide C14R Combines Excellent Activity against the Major Opportunistic Human Pathogen Pseudomonas aeruginosa with Low Cytotoxicity
Last-Save-Date: 2024-01-09T07:08:07Z
pdf:docinfo:creator_tool: LaTeX with hyperref
access_permission:fill_in_form: true
pdf:docinfo:keywords: antimicrobial peptides; clinical isolates; pore-formation; Pseudomonas aeruginosa
pdf:docinfo:modified: 2024-01-09T07:08:07Z
meta:save-date: 2024-01-09T07:08:07Z
pdf:encrypted: false
dc:title: The Designed Pore-Forming Antimicrobial Peptide C14R Combines Excellent Activity against the Major Opportunistic Human Pathogen Pseudomonas aeruginosa with Low Cytotoxicity
modified: 2024-01-09T07:08:07Z
cp:subject: The diminishing portfolio of mankind?s available antibiotics urges science to develop novel potent drugs. Here, we present a peptide fitting the typical blueprint of amphipathic and membrane-active antimicrobial peptides, denominated C14R. This 2 kDa peptide consists of 16 amino acid residues, with seven being either hydrophobic, aromatic, or non-polar, and nine being polar or positively charged, strictly separated on opposite sides of the predicted -helix. The affinity of the peptide C14R to P. aeruginosa membranes and its intrinsic tendency to productively insert into membranes of such composition were analyzed by dynamic simulations. Its biological impact on the viability of two different P. aeruginosa reference strains was demonstrated by determining the minimal inhibitory concentrations (MICs), which were found to be in the range of 10?15 g/mL. C14R?s pore-forming capability was verified in a permeabilization assay based on the peptide-triggered uptake of fluorescent dyes into the bacterial cells. Finally, the peptide was used in radial diffusion assays, which are commonly used for susceptibility testing of antimicrobial peptides in clinical microbiology. In comparison to reference strains, six clinical P. aeruginosa isolates were clearly affected, thereby paving the way for further in-depth analyses of C14R as a promising new AMP drug in the future.
pdf:docinfo:subject: The diminishing portfolio of mankind?s available antibiotics urges science to develop novel potent drugs. Here, we present a peptide fitting the typical blueprint of amphipathic and membrane-active antimicrobial peptides, denominated C14R. This 2 kDa peptide consists of 16 amino acid residues, with seven being either hydrophobic, aromatic, or non-polar, and nine being polar or positively charged, strictly separated on opposite sides of the predicted -helix. The affinity of the peptide C14R to P. aeruginosa membranes and its intrinsic tendency to productively insert into membranes of such composition were analyzed by dynamic simulations. Its biological impact on the viability of two different P. aeruginosa reference strains was demonstrated by determining the minimal inhibitory concentrations (MICs), which were found to be in the range of 10?15 g/mL. C14R?s pore-forming capability was verified in a permeabilization assay based on the peptide-triggered uptake of fluorescent dyes into the bacterial cells. Finally, the peptide was used in radial diffusion assays, which are commonly used for susceptibility testing of antimicrobial peptides in clinical microbiology. In comparison to reference strains, six clinical P. aeruginosa isolates were clearly affected, thereby paving the way for further in-depth analyses of C14R as a promising new AMP drug in the future.
Content-Type: application/pdf
pdf:docinfo:creator: Vanessa Mildenberger, Daniel Alpízar-Pedraza, Ernesto M. Martell-Huguet, Markus Krämer, Grigory Bolotnikov, Anselmo J. Otero-Gonzalez, Tanja Weil, Armando Rodriguez-Alfonso, Nico Preising, Ludger Ständker, Verena Vogel, Barbara Spellerberg, Ann-Kathrin Kissmann and Frank Rosenau
X-Parsed-By: org.apache.tika.parser.DefaultParser
creator: Vanessa Mildenberger, Daniel Alpízar-Pedraza, Ernesto M. Martell-Huguet, Markus Krämer, Grigory Bolotnikov, Anselmo J. Otero-Gonzalez, Tanja Weil, Armando Rodriguez-Alfonso, Nico Preising, Ludger Ständker, Verena Vogel, Barbara Spellerberg, Ann-Kathrin Kissmann and Frank Rosenau
meta:author: Vanessa Mildenberger, Daniel Alpízar-Pedraza, Ernesto M. Martell-Huguet, Markus Krämer, Grigory Bolotnikov, Anselmo J. Otero-Gonzalez, Tanja Weil, Armando Rodriguez-Alfonso, Nico Preising, Ludger Ständker, Verena Vogel, Barbara Spellerberg, Ann-Kathrin Kissmann and Frank Rosenau
dc:subject: antimicrobial peptides; clinical isolates; pore-formation; Pseudomonas aeruginosa
meta:creation-date: 2024-01-09T06:42:49Z
created: 2024-01-09T06:42:49Z
access_permission:extract_for_accessibility: true
access_permission:assemble_document: true
xmpTPg:NPages: 15
Creation-Date: 2024-01-09T06:42:49Z
pdf:charsPerPage: 3937
access_permission:extract_content: true
access_permission:can_print: true
meta:keyword: antimicrobial peptides; clinical isolates; pore-formation; Pseudomonas aeruginosa
Author: Vanessa Mildenberger, Daniel Alpízar-Pedraza, Ernesto M. Martell-Huguet, Markus Krämer, Grigory Bolotnikov, Anselmo J. Otero-Gonzalez, Tanja Weil, Armando Rodriguez-Alfonso, Nico Preising, Ludger Ständker, Verena Vogel, Barbara Spellerberg, Ann-Kathrin Kissmann and Frank Rosenau
producer: pdfTeX-1.40.25
access_permission:can_modify: true
pdf:docinfo:producer: pdfTeX-1.40.25
pdf:docinfo:created: 2024-01-09T06:42:49Z